The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17β‐hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma
The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17β‐hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma
复制标题
DOI：
10.1046/j.1365-2265.2003.01766.x
复制
发表时间：
2003-06
影响因子：
3.2
通讯作者：
H. Utsunomiya;Takashi Suzuki;K. Ito;T. Moriya;R. Konno;Shinji Sato;N. Yaegashi;K. Okamura;H. Sasano
中科院分区：
文献类型：
--
作者：
H. Utsunomiya;Takashi Suzuki;K. Ito;T. Moriya;R. Konno;Shinji Sato;N. Yaegashi;K. Okamura;H. Sasano
目的雌激素的原位代谢和合成在子宫内膜样腺癌的发生发展中起重要作用。大约3%-5%的这些肿瘤患者年龄在40岁以下，其中一些人已经接受了单独的孕激素治疗，作为非典型子宫内膜增生和腺癌的主要治疗方法，以保持他们的生育能力。甲羟孕酮已被广泛用于治疗乳腺和子宫内膜疾病，作为一种内分泌治疗方法。然而，孕激素治疗后体内雌激素代谢变化的细节仍未完全阐明。
objective In situ metabolism and synthesis of oestrogens are considered to play important roles in the pathogenesis and development of human endometrial endometrioid adenocarcinoma. Approximately 3–5% of patients with these neoplasms are under age 40, some of whom have been treated with progestogen alone as a primary therapy for both atypical endometrial hyperplasia and adenocarcinoma in order to preserve their fertility. Medroxyprogesterone acetate (MPA) has been used extensively in the treatment of both breast and endometrial disorders as an endocrine therapy. However, details of the alterations of in situ oestrogen metabolism following progestogen treatment have yet to be fully elucidated.